MRNA Stock Surges As Flu Win And CAR-T Hype Fuel Breakout

Moderna Inc. stocks have been trading up by 8.25 percent after strong mRNA pipeline progress fueled investor optimism.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading MRNA

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways

FDA advisers unanimously backed Moderna’s mRNA-1010/mFLUSIVA flu shot for adults 50–64 and 65+, clearing a major regulatory hurdle ahead of the 2026/08/05 PDUFA date.
The positive flu panel and mFLUSIVA backing sparked an immediate MRNA pop of around 4% intraday as traders priced in higher odds of commercialization.
At Science Day, Moderna highlighted oncology and autoimmune programs, including T‑cell engagers, an ovarian cancer candidate, and in vivo CAR‑T mRNA-6007, showcasing a broader mRNA platform.
Jefferies stayed cautious with a Hold and $45 target, flagging that meaningful flu revenue for MRNA likely starts closer to 2027 despite regulatory momentum.
Piper Sandler lifted its MRNA target to $77 with an Overweight rating as shares ripped 8–14% in recent sessions, helped by enthusiasm around in vivo CAR‑T plans and the expanding pipeline.

Live Update At 14:02:50 EDT: On Thursday, July 02, 2026 Moderna Inc. stock [NASDAQ: MRNA] is trending up by 8.25%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

MRNA has been trading like a classic momentum biotech. Over the recent multi-week stretch, shares climbed from the high‑$40s to a close of $78.47 on 2026/07/02. That’s a powerful uptrend, with a series of higher lows from roughly $46 to above $70, then a breakout run into the high‑$70s.

Intraday action on the latest session shows tight, controlled trading. MRNA opened near $73.75, spiked as high as $81.40, and settled back just under $80. The five‑minute candles show steady bids between $77 and $79, a sign that dip buyers are supporting the move rather than bailing at the first sign of weakness.

Fundamentally, Moderna is still burning cash. Quarterly revenue sits around $389M, while the company posted a net loss of about $1.34B and negative operating cash flow of roughly $630M. Margins are deeply negative and free cash flow is roughly -$692M, so MRNA is not trading on earnings power yet.

More Breaking News

But the balance sheet is solid for now. With about $5.21B in cash and short‑term investments and low debt (total debt‑to‑equity around 0.17), the company has runway to fund its pipeline. For traders, that combination—strong cash, big losses, and a hot catalyst path—often means volatility and sharp trend moves.

Why Traders Are Watching MRNA’s Momentum Spike

MRNA is back on a lot of screens because the story finally shifted from “post‑COVID slump” to “multi‑product mRNA platform.” The key catalyst: an FDA advisory committee voted 9‑0 that Moderna’s mRNA‑1010/mFLUSIVA flu vaccine has a favorable benefit‑risk profile for adults 50–64 and 65+. When a VRBPAC panel is that unanimous, traders know the odds of final approval are high.

FDA advisers also backed full approval of mFLUSIVA for adults 50–64 and accelerated approval for 65+, and the stock jumped about 4% intraday on that headline. Another report notes that advisers recommended the flu shot broadly for adults 50+, reinforcing the view that MRNA is poised to diversify beyond COVID vaccines into a large, recurring flu market.

The street reaction has been mixed but tilting bullish. Jefferies kept a Hold rating and a $45 target, reminding traders that real flu revenue for MRNA is likely back‑weighted toward 2027. That helps explain why this isn’t a straight line up: shorter‑term players have to trade sentiment and charts, not near‑term earnings.

On the other side, Piper Sandler raised its target from $69 to $77 and reiterated an Overweight stance. Another note pegs the stock around $63.24, up 5.8% on the day, with the average Wall Street target still closer to $48.25 and an overall Hold view. That disconnect—bullish upgrades versus cautious consensus—creates exactly the kind of tension momentum traders like. If MRNA keeps hitting clinical and regulatory milestones, there’s room for further target hikes and multiple expansion.

Add in the recent price action: reports of MRNA up 8.7% intraday to $64.95, and another session where shares ripped 14.2% to $68.23 without fresh news. That tells you sentiment is turning, shorts are likely getting squeezed, and day traders are piling into the volatility.

Science Day poured more fuel on the story. Moderna showed off validated T‑cell engager data in multiple myeloma (mRNA‑2808), an ovarian cancer follow‑on (mRNA‑2151), and an in vivo CAR‑T candidate (mRNA‑6007). One update said MRNA nearly jumped 12% after plans were announced to begin clinical development of mRNA‑6007 in 2027, with several analysts raising price targets. For traders, that’s a classic “future promise meets current price” setup: no near‑term revenue, but big optionality that can drive sharp repricings as the narrative heats up.

Conclusion

For active traders, MRNA is evolving into a clean case study in how catalysts, charts, and sentiment collide. The unanimous flu‑vaccine panel vote gives Moderna a high‑confidence path toward its first major non‑COVID vaccine franchise, with a PDUFA decision target around 2026/08/05. The Science Day updates and mRNA‑6007 in vivo CAR‑T plans reposition Moderna as a broader mRNA therapeutics platform, not just a pandemic winner.

At the same time, the financials remind us this is still a high‑risk biotech name. Losses are steep, free cash flow is deeply negative, and meaningful flu revenue likely doesn’t show up in size until around 2027. The balance sheet is strong enough to fund that journey, but traders should treat every run as a trading opportunity, not a guarantee.

The recent 8–14% daily swings show just how quickly MRNA can move when headlines and momentum line up. That’s exactly the environment where tight risk management matters. As Tim Sykes likes to say, “The best traders don’t predict the future, they react to the present and cut losses quickly.” Just as importantly, success in trading MRNA starts before the market even opens; as Tim Bohen, lead trainer with StocksToTrade says, “Preparation is half the trade. By the time the bell rings, my decisions are nearly made.”. For MRNA, that means respecting the trend, watching the catalysts, and never overstaying when the chart turns against you.

This analysis is for educational and research purposes only and is not investment advice.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!